Researchers GAMBLING on Coronavirus Antibody Tests

Scientists and doctors, during the COVID-19 Pandemic, are trying to find ways to return to normal life as soon as possible. However, amid so much uncertainty, we sometimes have to make risky decisions about which method will be more appropriate.
In week 2 of April, laboratories in the United States began testing for COVID-19 by detecting antibodies against the SARS-CoV-2 coronavirus that causes it using antibody tests administered to hundreds of thousands of people.
However, this also brought controversy. The reason for the debate is that PCR-based tests identify genetic sequences "belonging to the virus." By contrast, an antibody test measures the body’s virus-directed immune system response. In other words, the antibodies to be detected vary according to the individual’s immune status and require more detailed interpretation.
The laboratory tests used to diagnose the novel coronavirus can be seen below:

Although antibodies can indicate whether someone is currently infected with the coronavirus, some researchers claim that this test could be useful where PCR tests are unavailable. At present, the main question about coronavirus is whether the antibodies formed in people who recover from COVID-19 protect against becoming infected with it again.
Many clinics and laboratories in the United States are working to scale up antibody results in the fight against the pandemic. Amid this uncertainty, however, investments of hundreds of thousands of dollars amount to bets on how effective the results will be.
Following the rise in cases, the United States has become the world’s COVID-19 epicenter. If the bets on antibody testing pay off, the results are thought likely to provide an important model for combating the pandemic.
Keith Jerome, director of the clinical virology division at the University of Washington School of Medicine in Seattle, says the following about antibody studies. “If we wait for every question to be answered, we will not be ready for months. We should not focus only on perfection and ignore the good. We need to act as soon as possible.”
A Rapid Test Indicating Infection
In mid-March, Rashid Chotani, an infectious disease epidemiologist at CareLife Medical, began administering rapid antibody tests in his office. This rapid test, which gives results in 10 minutes using a drop of blood from a fingertip, was given to healthcare workers, essential workers such as construction workers, and family members of people with the disease. These asymptomatic people at risk of COVID-19 were screened because they would not receive a PCR test (many hospitals in the United States perform PCR tests only on people with symptoms).
In general, our immune system produces different waves of antibodies to fight invaders. One of the first waves, called Ig M (immunoglobulin M), is produced about 4-10 days after a coronavirus infection. An antibody test can therefore miss the infection at a very early stage. Chotani describes the difficulty as follows: “Someone who had a positive antibody test 3 weeks ago also had a positive confirmatory test (a second test). We then wanted to confirm the result with an official PCR test using a nasal swab. We had to wait about 2 days for the result, and during this time we advised the doctors not to treat. Unfortunately, this was a dilemma.”
In many US hospitals, asking doctors to provide COVID-19 treatment is against the rules unless there are symptoms or a positive PCR test. However, this rule creates tension for many healthcare workers, because coronavirus infections without symptoms may account for around 40% of cases. Nevertheless, Chotani suggests that rapid antibody tests could help prevent viral spread in workplaces where employees cannot undergo PCR screening.

Another dilemma is that rapid antibody results can be incorrect. According to manufacturer Boston Biopharma, the test Chotani uses gives false-positive results at a rate of 2% (saying someone is "ill" when they are not) and false-negative results at a rate of 15% (saying someone is "not ill" when they are). Although around 70 antibody tests have been developed over the past 1 month, the FDA has not yet approved any of them. The FDA and the World Health Organization recommend PCR-based tests to "confirm" a case associated with the virus.
However, relying on PCR tests for a definitive diagnosis is also controversial. The Chinese Clinical Guideline has been updated to count IgM positivity as an indicator of acute coronavirus infection. Experts say such flaws can occur in many outbreaks because of the urgency of the situation, shortages of PCR tests and potential inaccuracies in testing; for example, the sensitivity of the first PCR test was reported to be between 30-60%. Ranu Dhillon, an outbreak response specialist at Harvard Medical School in Boston, says that someone with a positive IgM test should be considered infected and isolated at home until proved otherwise. For these reasons, there are also studies reporting that lung computed tomography (BT) is the most appropriate method for diagnosing COVID-19.
A Screening Test Indicating Protection
After an infection has passed, the immune system produces a certain class of virus-remembering antibodies gradually. In some diseases, the virus is encountered by IgG antibodies, which render it harmless so that it cannot damage cells. This antibody, called IgG (immunoglobulin G) and produced through the immune response, is the second wave of antibodies to form after IgM.
An immunity test for COVID-19 shows protective antibodies that prevent a person from becoming ill again. Some centers are observing whether healthcare workers at high risk of infection who test positive for IgG have a low risk of contracting COVID-19 again.
In another study, antibody levels detected in IgG-positive blood samples are also measured using a more complex test called ELISA. The study aims to assess how well IgG antibodies can prevent coronavirus from infecting cells in a cell culture. If the researchers achieve this, they think they could obtain plasma from the blood of the individuals who provided the samples and help treat people with COVID-19.
Meanwhile, researchers at Beaumont Health in Detroit, Michigan, are screening 38,000 doctors, technicians and other hospital staff for IgG antibodies using an ELISA diagnostic test from EuroImmun. This test will allow them to learn whether a certain antibody level is needed for protection. Studies of antibody status are continuing at full speed at many centers worldwide. Some experts believe antibody test results cause errors and confusion.
Antibody tests can be seen as a litmus test for scientists’ personalities (litmus paper is one of the chemical indicators used to distinguish acids from bases in solutions). However, it is important to recognize that the uncertainty being experienced is inherent in scientific processes.
Scott Boyd, an immunologist at Stanford University in California, says the following. “Some people are extremely uncomfortable because we do not have much information, while others say this is the best we can do right now. We have to keep doing things despite everything.”
*
- Related topic: What Should We Know About Blood Products and CONVALESCENT PLASMA Treatment During the Coronavirus Outbreak?
*
- ALL OUR CORONAVIRUS ARTICLES *
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.